Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market Growth | DelveInsight

DelveInsight projects the seven-major-market PNH treatment market, valued at approximately $1.5 billion in 2025, will grow at a 7.1% CAGR through 2036 as novel complement-targeted therapies expand treatment options. Regeneron expects Phase III PNH results for pozelimab plus cemdisiran in Q4 2026 or Q1 2027, while Novo Nordisk's zaltenibart, NovelMed's ruxoprubart and NM5072, and Kira's KP104 advance through clinical development. The outlook is supported by increasing PNH diagnosis and demand for therapies that address breakthrough hemolysis and transfusion dependence, though the candidates remain investigational.

Analysis

This is not a near-term earnings event; it is a reminder that PNH is shifting from a durable oligopoly toward mechanism-based segmentation. AZN's Alexion franchise has the largest absolute revenue pool at risk, but payer-mandated switching should remain slow because infection-management protocols, physician familiarity, and long-duration dosing convenience create substantial inertia. The more relevant 6-18 month risk is pricing: multiple credible alternatives can reduce net price and raise gross-to-net discounts even if incumbent patient share remains broadly intact.

REGN and ALNY have the only disclosed late-stage catalyst with enough clinical maturity to influence valuation in the next two quarters. A positive result must show more than biochemical control: superiority or meaningful differentiation on breakthrough hemolysis, transfusion avoidance, dosing burden, and infection outcomes is required to support premium pricing against established C5 and proximal inhibitors. NVO's asset is strategically interesting across complement diseases but is too early for PNH to matter financially; its value is optionality in a broader renal/hematology platform rather than a 2027 revenue driver.

The consensus may overestimate market-expansion economics from greater diagnosis and innovation. In an ultra-rare disease, each additional entrant fragments a limited treated population, and clinical differentiation may accrue to patients while much of the economic surplus shifts to payers. APLS is directionally exposed because proximal-pathway competition weakens the scarcity value of its mechanism, although PNH alone is unlikely to move consolidated estimates. Treat the underlying source as promotional market research rather than independently validated demand or revenue forecasting.

Key Decisions for Investors

• No immediate position from this release; maintain an alert on REGN's pozelimab-cemdisiran Phase III dataset expected over the next 1-2 quarters. Consider a 3-6 month tactical long only if disclosed efficacy and safety support a credible switch case versus Ultomiris, not merely non-inferior complement suppression.
• Maintain a 6-18 month negative relative-value bias on AZN's complement-franchise multiple versus REGN, but do not short AZN outright given diversification. The thesis is falsified if Alexion reports stable net pricing and continued share retention despite new proximal-pathway launches.
• Avoid extrapolating NVO's PNH optionality into near-term estimates. Reassess only at Phase II efficacy data; a clean, differentiated signal in both PNH and renal disease would justify attributing platform value, while safety or insufficient efficacy would eliminate the strategic-premium case.
• Monitor APLS quarterly PNH patient starts, net price realization, and guidance commentary. A material deceleration in new starts or increased rebate pressure would support a hedge via short APLS versus long REGN; absent those data, competitive-risk framing alone is insufficient for a trade.